Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia

Circulation

Volumn 96, Issue 6, 1997, Pages 1803-1808

  Tonstad, Serena ^a,c   Refsum, Helga ^b   Ueland, Per Magne ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Genetics; Homocysteine; Hypercholesterolemia; Pediatrics; Risk factors

Indexed keywords

HOMOCYSTEINE;

ADOLESCENT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY RISK; CORRELATION FUNCTION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD;

EID: 0030852520     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.6.1803     Document Type: Article

References (47)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York, NY: McGraw-Hill; 1995:1981-2030.
2. The Expert Panel, National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:525-584.
3. Ose L, Tonstad S. The detection and management of dyslipidaemia in childhood and adolescence. Acta Pædiatr. 1995;84: 1213-1215.
4. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129: 42-49.
5. Betteridge DJ. Lipid disorders. In: Brook CGD, ed. Paediatric Endocrinology, 3rd ed. Oxford, UK: Blackwell Science; 1995: 694-712.
6. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb. 1991;11:290-297.
7. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499.
8. Heiberg A, Slack J. Family similarities in the age at coronary death in familial hypercholesterolaemia. BMJ. 1977;2:493-495.
9. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BAJ. 1991;303:893-896.
10. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, And Endothelial Function. New York, NY: Marcel Dekker; 1992:183-236.
11. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
12. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
13. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346: 1395-1398.
14. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 1996;58:17-20.
15. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvåle G. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995; 274:1526-1533.
16. Nygård O, Refsum H, Ueland PM. Stensvold I, Nordrehaug JE, Kvåle G, Vollset SE. Coffee consumption and total plasma homocysteine: the Hordaland Homocysteine Study. Am J Clin Nutr. 1997;65:136-143.
17. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
18. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase locus. Nat Genet. 1995;10:111-113.
19. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346: 1070-1071.
20. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
21. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentration. Circulation. 1996;93:7-9.
22. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter): the Hordaland Homocysteine Study. J Clin Invest. 1996;98: 2174-2183.
23. Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L. Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects. Atherosclerosis. 1994;111: 175-182.
24. Leren TP, Sundvold H, Rødningen OK, Tonstad S, Solberg K, Ose L, Berg K. Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia. Hum Genet. 1995;95: 671-676.
25. Tanner JM. Growth at Adolescence, 2nd ed. Oxford, UK: Blackwell; 1962.
26. Frost Andersen L, Nes M, Lillegaard IT, Sandstad B, Bjørneboe GE, Drevon CA. Evaluation of a quantitative food frequency questionnaire used in a group of Norwegian adolescents. Eur J Clin Nutr. 1995;49:543-554.
27. Tonstad S, Sivertsen M. Dietary adherence in familial hypercholesterolemia. Am J Clin Nutr. 1997;65:1018-1026.
28. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem. 1993;39:263-271.
29. Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem. 1989;35:1921-1927.
30. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995;75: 132-136.
31. Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, Ueland PM. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Pediatr Res. 1996;40:47-52.
32. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bønaa KH. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and controls. Arterioscler Thromb Vasc Biol. 1996;16:984-991.
33. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2: 386-389.
34. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation. 1993;88:1973-1998.
35. Kang S-S, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992; 12:279-298.
36. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
37. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis. 1996;121:293-294.
38. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
39. De Franchis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, de Stefano V, Margaglione M, Mazzola G, di Minno G, Andria G. Elevated total plasma homocysteine and 677C-T mutation of the 5.10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet. 1996;59:262-264.
40. Schneede J, Dagnelie PC, van Staveren WA, Vollset SE, Refsum H, Ueland PM. Methylmalonic acid and homocysteine in plasma as indicators of functional cobalamin deficiency in infants on macrobiotic diets. Pediatr Res. 1994;36:194-201.
41. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 1994;236:633-641.
42. Ubbink JB. Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr Rev. 1994;52:383-387.
43. Stampfer MJ, Rimm EB. Folate and cardiovascular disease. JAMA. 1996;275:1929-1930.
44. Bostom AG, Yanek L, Hume AL, Eaton CB, McQuade W, Nadeau M, Perrone G, Jacques PF, Seihub J. High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease. Atherosclerosis. 1994;111:267-270.
45. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA. 1996;275: 1893-1896.
46. Fraser GE. Diet and coronary heart disease: beyond dietary fats and low-density-lipoprotein cholesterol. Am J Clin Nutr. 1994; 59(suppl):1117-1123.
47. Malinow MR. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990; 81:2004-2006.